Sanofi stock surges as Dupixent shows benefit in smokers with lung disease and meets Phase 3 goals
JHVEPhoto Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals (NASDAQ: REGN) Dupixent met the primary objective and all primary secondary objectives of a Phase 3 trial to treat adults who were current or former smokers with chronic obstructive pulmonary disease (COPD). The French pharmaceutical giant said Dupixent (dupilumab) showed the potential to become the first biologic drug…
